A new study supports the use of virtual patients and in silico clinical studies to evaluate the effectiveness of blue light to reduce the symptoms of psoriasis.

Researchers also demonstrated that this in silico approach can be used to improve the treatment response of patients with psoriasis to blue light by modifying the settings of the therapeutic protocol, as reported in the study published in Systems Medicine, an open access journal from Mary Ann Liebert Inc, publishers.

The researchers note that the current computational model for studying the efficacy of blue light therapy only reproduces the response in the average patient in clinical trials and does not take into account individual variations amongst patients. Use of a computational model combined with a refined pool of virtual patients can adequately capture the patient variability in the response to treatment with blue light and the decrease in disease severity seen in previous clinical investigations.

The authors suggest that a minimum of 2,500 virtual patients, which they refined down from an initial pool of 500,000 virtual patients, are needed to reproduce the responses seen in clinical investigations, they explain in a media release from Mary Ann Liebert Inc/Genetic Engineering News.

“This is a highly promising approach towards using statistical learning on virtual patient populations to draw actionable clinical conclusions on real patients, and thus a major step forward to precision medicine,” says Co-Editor-in-Chief Prof Dr Jan Baumbach from Technical University of Munich, in the release.

[Source(s): Mary Ann Liebert Inc/Genetic Engineering News, EurekAlert]